Antiangiogenic therapy: Markers of response, "normalization" and resistance.
Fiche publication
Date publication
août 2018
Journal
Critical reviews in oncology/hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FAIVRE Béatrice
Tous les auteurs :
El Alaoui-Lasmaili K, Faivre B
Lien Pubmed
Résumé
Currently in cancer treatment, one premise is to use antiangiogenic therapies in association with chemotherapy or radiotherapy to augment their efficacy by benefiting from the vascular "normalization" induced by antiangiogenic therapy. This concept defines the time during which the tumor blood vessels adopt normal-like morphology and functionality, i.e. the blood vessels become more mature, the perfusion augments and hypoxia decreases. To date, there is such a diversity of treatment protocols where the type of antiangiogenic to adopt, its dose and duration of administration are different, that knowing when and how to treat is problematic. In this review, we analyzed thoroughly preclinical and clinical studies that use antiangiogenic treatments to benefit from the "normalization" and showed that the effects depend on the type of antiangiogenic administrated (anti-VEGF, anti-VEGFR, Multi-Kinase Inhibitor) and on the duration of treatment. Finally, biomarkers of "normalization" and resistance that could be used in the clinic are presented.
Mots clés
Antiangiogenic therapy, Cancer, Chemotherapy, Radiotherapy, Vascular normalization
Référence
Crit. Rev. Oncol. Hematol.. 2018 Aug;128:118-129